Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Concha Boqué"'
Autor:
Beatriz Colom-Fernández, Anna Kreutzman, Ana Marcos-Jiménez, Valentín García-Gutiérrez, Carlos Cuesta-Mateos, Itxaso Portero-Sainz, Yaiza Pérez-García, Luis Felipe Casado, Fermín Sánchez-Guijo, Joaquín Martínez-López, Rosa M. Ayala, Concha Boqué, Blanca Xicoy, Isabel Montero, César Soto, Raquel Paz, Gabriela Silva, Lorena Vega-Piris, Juan Luis Steegmann, Cecilia Muñoz-Calleja
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been lin
Externí odkaz:
https://doaj.org/article/8076d19c9d6e4febaa5ad4e8c9a321dd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Silvia, Marcé, Lurdes, Zamora, Marta, Cabezón, Blanca, Xicoy, Concha, Boqué, Cristalina, Fernández, Javier, Grau, José-Tomás, Navarro, Alberto, Fernández de Sevilla, Josep-Maria, Ribera, Evarist, Feliu, Fuensanta, Millá
Publikováno v:
Medicina clinica. 141(3)
Background and objectives Tyrosine kinase inhibitors (TKI) have improved the management of patients with chronic myeloid leukemia (CML). However, a significant proportion of patients do not achieve the optimal response or are resistant to TKI. ABL ki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a48c002154cd7719118648f837c2e9bb
https://pubmed.ncbi.nlm.nih.gov/23462544
https://pubmed.ncbi.nlm.nih.gov/23462544
Autor:
Concha Boqué, Eva Domingo-Domenech, Albert Grañena, Alberto Valiente, Katy Perez-Equiza, Ana Aventin, Alicia Domingo-Clarós, María José Calasanz
Publikováno v:
Cancer genetics and cytogenetics. 139(1)
We report two adult patients with Philadelphia chromosome positive (Ph+) B-cell acute lymphoblastic leukemia (ALL) who presented an additional dic(16;18)(q11;p11) that, to the best of our knowledge, has never been previously reported. Fluorescence in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae41c42b43b542b242192011b023745a
https://pubmed.ncbi.nlm.nih.gov/12547162
https://pubmed.ncbi.nlm.nih.gov/12547162
Autor:
Olga García, Josep-Maria Ribera, Lurdes Zamora, Fuensanta Millá, Blanca Xicoy, Marc Sorigue, David Gallardo, Marisol Xandri, Evarist Feliu, Patricia Velez, C. Fernández, Silvia Marcé, Concha Boqué, Marta Cabezón, Enric Casanova
Publikováno v:
Blood. 124:5562-5562
INTRODUCTION: Several mutations have been described in patients with BCR-ABL1 –negative chronic myeloproliferative neoplasms, including primary myelofibrosis (PMF). The most frequent mutation is JAK2 V617F, followed by calreticulin exon 9 (CALR), M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::805e6fd8e8af2cbdd3de6f976e7efb36
https://doi.org/10.1182/blood.v124.21.5562.5562
https://doi.org/10.1182/blood.v124.21.5562.5562
Autor:
Evarist Feliu, Diana Marcela Ruíz Domínguez, Josep-Maria Ribera, Lurdes Zamora, Neus Ruiz-Xivillé, Esther Plensa, Silvia Marcé, Marta Cabezón, Concha Boqué, Imma Portal, Isabel Granada, Blanca Xicoy, Esther Alonso, C. Fernández, Joan Buch, Dolors Vela, Natividad Lopez, José-Tomás Navarro, Lluís Rodríguez, David Gallardo, Marisol Xandri, Luz San Miguel, Olga García, Fuensanta Millá
Publikováno v:
ResearcherID
Abstract 1437 JAK2 mutation testing and karyotye are routinely used for diagnosis of myeloproliferative neoplasms (MPNs) but they have not been incorporated into risk stratification. Although JAK2V617F mutation in MPNs has been one of the most semina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa665bbdbae7c8562b51628a34cd0520
https://doi.org/10.1182/blood.v120.21.1437.1437
https://doi.org/10.1182/blood.v120.21.1437.1437
Autor:
Lluís Rodríguez, Alberto Fernández de Sevilla, Patricia Velez, Evarist Feliu, Imma Portal, Concha Boqué, Lurdes Zamora, José-Tomás Navarro, Marta Cabezón, Blanca Xicoy, Diana Marcela Ruíz Domínguez, Josep-Maria Ribera, Silvia Marcé, Esther Plensa, Javier Grau, Marisol Xandri, Fuensanta Millá, Cristalina Fernandez, Jorge Medina, Jordi Ribera
Publikováno v:
Blood. 118:4442-4442
Abstract 4442 Introduction: Chronic myeloid leukemia (CML) is a model of disease in the development of targeted therapies. Tyrosine kinase inhibitors (TKIs) have transformed the approach to management of CML and have dramatically improved patients' o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::207975a6a44748257835dfb90f7b8838
https://doi.org/10.1182/blood.v118.21.4442.4442
https://doi.org/10.1182/blood.v118.21.4442.4442
Autor:
Silvia Marcé, Marta Cabezón, Cristalina Fernandez, Javier Grau, Diana Marcela Ruíz Domínguez, Blanca Xicoy, Josep-Maria Ribera, David Gallardo, Alberto Fernández de Sevilla, Jordi Ribera, Fuensanta Millá, Isabel Granada, Concha Boqué, Lurdes Zamora, Evarist Feliu
Publikováno v:
Blood. 116:4838-4838
Abstract 4838 Introduction: Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of BCR/ABL fusion gene. The resulting protein has a high tyrosine kinase (TK) activity. The first-line treatment for CML is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f70a8b3bcecb6f1504ea307a277b6a5
https://doi.org/10.1182/blood.v116.21.4838.4838
https://doi.org/10.1182/blood.v116.21.4838.4838